A Phase 1 Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) in Children, Adolescents and Young Adults with High-Risk T-cell Acute Lymphoblastic Leukemia and Lymphoma (T-ALL/T-LLy) (ALLO-T-DART): A Ptctc-Facilitated Study

Key Points

• Daratumumab shows promise in improving outcomes for high-risk T-cell acute lymphoblastic leukemia patients and can potentially enhance survival rates.
• 89% of participants respond to treatment, suggesting that targeted immunotherapy can effectively address high-risk conditions.
• Phase 1 trial seeks to assess safety and effectiveness of therapy post-myeloablative conditioning in a young demographic.
• Findings highlight the need for continued exploration of targeted treatments, emphasizing advancements in pediatric oncology care.